U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. Drug Safety and Availability
  4. Postmarket Drug Safety Information for Patients and Providers
  5. Darunavir Ethalolate (marketed as Prezista) Information
  1. Postmarket Drug Safety Information for Patients and Providers

Darunavir Ethalolate (marketed as Prezista) Information

Prezista is a human immunodeficiency virus (HIV-1) protease inhibitor indicated for the treatment of HIV-1 infection in adult patients. Prezista is also indicated for the treatment of HIV-1 infection in pediatric patients 3 years of age and older. Prezista must be co-administered with ritonavir (Prezista/ritonavir) and with other antiretroviral agents.

Adverse reactions or quality problems experienced with the use of this Product may be reported to the FDA's MedWatch Adverse Event Reporting program using the contact information at the bottom of this page.

Regulatory History and Labeling from Drugs@FDA

Back to Top